Retatrutide
Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Who's worth your money for Retatrutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 26 scored sellers
$1512 · 480mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$625 · 1000mg · 100.0% purity
Most tested
61 independent COAs on file
$404 · 150mg · 99.8% purity
Average price
$6.00/mg
Sellers
50
45-day trend
-0.5%
41 of 50 sellers have a current price· 5 stale hidden· 10 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 5d ago · stale
$3.15/mg -47.5% vs avg$1512
480mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 5d ago · stale
$8.83/mg +47.2% vs avg$530
60mg
- 🇺🇸 Prime Peptides96
✓ verified at source · 1h ago
$1.83/mg -69.5% vs avg$110
60mg
- 🇺🇸 Sunrise Bioresearch95
via Disclosed Labs · 5d ago · stale
$0.63/mg -89.6% vs avg$625
1000mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 5d ago · stale
$2.69/mg -55.1% vs avg$404
150mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 5d ago · stale
$4.18/mg -30.3% vs avg$251
60mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 5d ago · stale
$5.56/mg -7.4% vs avg$200
36mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · 5d ago · stale
$5.33/mg -11.1% vs avg$160
30mg
- Nova Peptides94
via Disclosed Labs · 5d ago · stale
$6.50/mg +8.3% vs avg$325
50mg
no purity - 🇺🇸 Ignite Peptides93
via Disclosed Labs · 5d ago · stale
$6.00/mg 0% vs avg$120
20mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Retatrutide
Get one email when the market actually moves — no newsletter, no noise.
About Retatrutide
CAS
2381089-83-2
Molecular formula
C221H342N46O68
Sequence
YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS
Typical dose range
0.5–12 mg once weekly subcutaneous (Phase 2 titration; 2–8 mg most studied maintenance range)
Half-life
~6 days
COAs for Retatrutide
551 third-party tests across 55 vendors. Each card links to the full report.
For
Retatrutide
by CertaPeptides· batch CP-2607-RET10
For
Retatrutide
by CertaPeptides· batch CP-2608-RET20
For
Retatrutide
by CertaPeptides· batch CP-2608-RET5
For
Retatrutide
by Peptide Partners· batch PX-L916
For
Retatrutide
by Arctic Lab supply· batch RT-2502-B
For
Retatrutide
by VoriLabs· batch RET-2608-B
For
Retatrutide
by VoriLabs· batch RET-2608-E
For
Retatrutide
by VoriLabs· batch RET-2608-F
For
Retatrutide
by jdbioworks· batch 2026-003
For
Retatrutide
by Reta One Labs· batch RT120826
For
Retatrutide
by Sunrise Bioresearch· batch GLP320JUL26-01
For
Retatrutide
by NovaForge Labs· batch LOT-2026-0521
For
Retatrutide
by NovaForge Labs· batch LOT - RT - QSCT1
For
Retatrutide
by Synthesis Peptides· batch 3GR10926
For
Retatrutide
by NovaForge Labs· batch LOT-RT-QSCO1
For
Retatrutide
by Arctic Lab supply· batch RT-2502-A
For
Retatrutide
by NovaForge Labs· batch 2026-ZGT-01
For
Retatrutide
by Reta One Labs· batch RT150826
For
Retatrutide
by CertaPeptides· batch CP-2607-RET30
For
Retatrutide
by CertaPeptides· batch CP-2606-RET50
For
Retatrutide
by Velora Biolabs· batch VBL-RT20-1
For
Retatrutide
by Velora Biolabs· batch VBL-RT15-1
For
Retatrutide
by Velora Biolabs· batch VBL-RT10-1
For
Retatrutide
by Velora Biolabs· batch VBL-RT30-1
23 citations indexed for Retatrutide
Study · 2026
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis
Rationale Retatrutide (LY3437943) is a novel long-acting triple incretin receptor agonist that targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).
rct · 2026
Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes
Context In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c and improved the lipid profiles of participants living with obesity, with and without T2D. Objective Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
animal · 2026
Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile
This study investigated whether Retatrutide, a triple incretin agonist, attenuates early diabetes-associated renal injury in a streptozotocin-induced rat model, and whether any protective effect is mediated through modulation of inflammatory cytokines (IL-1β, TNF-α) and HIF-1α gene expression in kidney tissue.
Study · 2026
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea
Background Retatrutide, an investigational triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, may be useful for treating obstructive sleep apnea (OSA).
Study · 2026
Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide
rct · 2026
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Background Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea.